Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has developed antibody-drug conjugates (ADCs) consisting of 19F6_Hu35V1 antibody covalently linked to a cytotoxic drug through a linker.
Research at Silexon Biotech Co. Ltd. has led to the identification of mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer, hepatitis B virus, hepatitis C virus and HIV infections.
Several recent patents from Vertex Pharmaceuticals Inc. have disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, Charcot-Marie-tooth disease, cough, urinary incontinence and multiple sclerosis.
An Otsuka Pharmaceutical Co. Ltd. patent describes pyrazolo[1,5-a]pyrimidine lysophosphatidic acid receptor 2 (LPAR2; EDG4) antagonists reported to be useful for the treatment of atopic dermatitis, psoriasis, eczema, scleroderma and pruritus, among others.
Trastuzumab deruxtecan (DS-8201a) is an antibody-drug conjugate used for the treatment of metastatic HER2+ breast cancer that is refractory to anti-HER2 therapy such as T-DM1, however, there is a lack of knowledge on acquired or innate resistance to the drug.
Researchers from Kbluebio Inc. and affiliated organizations recently reported the discovery and preclinical evaluation of a novel prohibitin-2 (PHB2) ligand as a potential candidate for the treatment of multiple myeloma (MM).
Eleven vaccines have now been approved by the World Health Organization for preventing COVID-19, but all exhibit drastically reduced activities after 6 months. Unlike vaccines that express only the spike protein as the immunogen, live attenuated vaccines have the potential to confer a broader and more durable protection.
Approximately 20,000 patients diagnosed with non-Hodgkin lymphomas died in 2022 despite current treatments; 30-40% of these cases involved diffuse large B-cell lymphoma (DLBCL). Monoallelic mutations in histone acetyltransferases (HATs) occur in over 39% of germinal center DLBCLs. Activation of intact wild-type alleles offers an opportunity to overcome the mutated allele.
Researchers from Taipei Medical University presented the discovery of novel store-operated calcium channel (SOC) inhibitors as potential anticancer candidates. Synthesis and optimization of a series of difluorobenzamide derivatives led to the discovery of MPT-0M004 as the lead candidate with promising SOC inhibitory activity. In vitro, both migration and invasion of colorectal cancer cells were significantly suppressed after 48 hours of treatment with MPT-0M004, with the growth inhibitory effect of the compound being similar to that seen for the reference SOC inhibitor.
RSS
